CompletedPhase 2NCT01187303
Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
Studying Nodular lymphocyte predominant Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Cologne
- Principal Investigator
- Andreas Engert, MDUniversity of Cologne
- Intervention
- Ofatumumab(drug)
- Enrollment
- 28 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2011 – 2015
Study locations (1)
- 1st Department of Medicine, Cologne University Hospital, Cologne, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01187303 on ClinicalTrials.govOther trials for Nodular lymphocyte predominant Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06098430Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)St. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT05886036Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM TrialNational Cancer Institute (NCI)
See all trials for Nodular lymphocyte predominant Hodgkin lymphoma →